Stock SANION SANA AB
Add to a list
To use this feature you must be a member
Log inSign up

Company SANA AB

Equities

SANION

SE0005794617

Biotechnology & Medical Research

Delayed Nasdaq Stockholm
Other stock markets
 03:18:47 2024-04-16 am EDT 		5-day change 1st Jan Change
1.86 SEK 0.00% Intraday chart for SANA AB -3.05% -54.06%
Mar. 01 Sana Biotechnology Shares Rise as Q4 Non-GAAP Net Loss Narrows MT
Mar. 01 Sector Update: Health Care Stocks Edge Higher Premarket Friday MT

Business Summary

Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.

Number of employees: 23

Sales per Business

SEK in Million2021Weight2022Weight Delta
Rare Diesease Patients Innovative Treatments
100.0 %
10 100.0 % 15 100.0 % +45.86%

Sales per region

SEK in Million2021Weight2022Weight Delta
Other European Countries
75.4 %
8 76.1 % 12 75.4 % +44.49%
Americas
24.6 %
3 23.9 % 4 24.6 % +50.16%

Managers

Managers TitleAgeSince
Palle Christophersen FOU
 Founder 66 10-12-31
Thomas Feldthus CEO
 Chief Executive Officer 64 10-12-31
Jørgen Drejer FOU
 Founder 69 10-12-31
Anita Milland DFI
 Director of Finance/CFO 56 13-12-31
Karin Nielsen CTO
 Chief Tech/Sci/R&D Officer 54 -
Rudolf Baumgartner CTO
 Chief Tech/Sci/R&D Officer 65 20-04-30
Janus Schreiber Larsen PRN
 Corporate Officer/Principal 52 -

Members of the board

Members of the board TitleAgeSince
Jørgen Drejer FOU
 Founder 69 10-12-31
Carl Johan Bertil Sundberg BRD
 Director/Board Member 66 14-12-31
Anna Ljung BRD
 Director/Board Member 44 18-01-18
Pierandrea Muglia BRD
 Director/Board Member 58 22-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 132,529,086 92,446,630 ( 69.76 %) 0 69.76 %

Shareholders

NameEquities%Valuation
Jørgen Drejer
2.512 %
2,794,741 2.512 % 503 920 kr
Tredje AP-fonden
2.005 %
2,229,911 2.005 % 402 075 kr
Formue Nord A/S
1.811 %
2,014,824 1.811 % 363 293 kr
Dan Peters
1.541 %
1,713,687 1.541 % 308 995 kr
Joakim Tedrof
1.154 %
1,284,076 1.154 % 231 532 kr
Hans Christian Thorn
1.062 %
1,181,853 1.062 % 213 100 kr
Thomas Feldthus
1.025 %
1,140,488 1.025 % 205 641 kr
Leif Andersson Consulting ApS
0.8433 %
938,066 0.8433 % 169 143 kr
Palle Christophersen
0.7862 %
874,571 0.7862 % 157 694 kr
FCG Fonder AB
0.3629 %
403,634 0.3629 % 72 779 kr

Company contact information

Saniona AB

Smedeland 26B

2600, Glostrup

+45 70 70 52 25

http://www.saniona.com
address SANA AB(SANION)

Group companies

NameCategory and Sector
Saniona A/S
Logo Saniona A/S

Saniona A/S

Miscellaneous Commercial ServicesCommercial Services

Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders.

Miscellaneous Commercial Services

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SANA AB Stock SANA AB
-53.62% 19.64M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.07% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.31% 97.22B
ARGENX SE Stock argenx SE
+4.22% 22.27B
BIONTECH SE Stock BioNTech SE
-16.64% 20.84B
GENMAB A/S Stock Genmab A/S
-4.50% 19.19B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.75% 16.76B
BEIGENE, LTD. Stock BeiGene, Ltd.
-22.81% 14.76B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.74% 13.54B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+23.34% 11.53B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. SANION Stock
  4. Company SANA AB